Sanofi ADR (SNY) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Sanofi ADR stock (SNY) is currently trading at $46.03. Sanofi ADR PE ratio is 19.21. Sanofi ADR PS ratio (Price-to-Sales) is 2.33. Analyst consensus price target for SNY is $57.68. WallStSmart rates SNY as Underperform.
- SNY PE ratio analysis and historical PE chart
- SNY PS ratio (Price-to-Sales) history and trend
- SNY intrinsic value — DCF, Graham Number, EPV models
- SNY stock price prediction 2025 2026 2027 2028 2029 2030
- SNY fair value vs current price
- SNY insider transactions and insider buying
- Is SNY undervalued or overvalued?
- Sanofi ADR financial analysis — revenue, earnings, cash flow
- SNY Piotroski F-Score and Altman Z-Score
- SNY analyst price target and Smart Rating
Sanofi ADR
📊 No data available
Try selecting a different time range
SNY Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Sanofi ADR (SNY)
SNY trades 90% above its Graham fair value of $24.79, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Sanofi ADR (SNY) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, price/book, profit margin. Concerns around peg ratio and return on equity. Mixed signals suggest waiting for clearer direction before acting.
Sanofi ADR (SNY) Key Strengths (3)
Large-cap company with substantial market presence
Trading at 1.31x book value, attractively priced
Strong profitability: $17 kept per $100 revenue
Supporting Valuation Data
Sanofi ADR (SNY) Areas to Watch (7)
Very expensive relative to growth, significant premium
Earnings barely growing at 2.40%
Very low institutional interest at 9.36%
Low profitability relative to shareholder equity
Thin operating margins with cost pressures present
Modest revenue growth at 6.90%
Revenue is fairly priced at 2.33x sales
Sanofi ADR (SNY) Detailed Analysis Report
Overall Assessment
This company scores 49/100 in our Smart Analysis, earning a D+ grade. Out of 10 metrics analyzed, 3 register as strengths (avg 8.3/10) while 7 fall into concern territory (avg 3.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Market Cap, Price/Book, Profit Margin. Valuation metrics including Price/Book (1.31) suggest the stock is attractively priced. Profitability is solid with Profit Margin at 16.70%.
The Bear Case
The primary concerns are PEG Ratio, EPS Growth, Institutional Own.. Some valuation metrics including PEG Ratio (4.32), Price/Sales (2.33) suggest expensive pricing. Growth concerns include Revenue Growth at 6.90%, EPS Growth at 2.40%, which may limit upside. Profitability pressure is visible in Return on Equity at 6.66%, Operating Margin at 14.30%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 6.66% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 6.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and EPS Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SNY Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SNY's Price-to-Sales ratio of 2.33x trades 23% below its historical average of 3.05x (8th percentile). The current valuation is 43% below its historical high of 4.09x set in Sep 2014, and 9% above its historical low of 2.15x in Feb 2009.
WallStSmart Analysis Synopsis
Data-driven financial summary for Sanofi ADR (SNY) · HEALTHCARE › DRUG MANUFACTURERS - GENERAL
The Big Picture
Sanofi ADR is a mature, profitable business with steady cash generation. Revenue reached 46.7B with 7% growth year-over-year. Profit margins of 16.7% are healthy, with room for further expansion as the business scales.
Key Findings
Generating 1.6B in free cash flow and 3.4B in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Dividend sustainability with a current yield of 9.2%. Watch payout ratio and free cash flow coverage.
Sector dynamics: monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive moves, and regulatory changes that could impact Sanofi ADR.
Bottom Line
Sanofi ADR is a well-established business delivering consistent profitability with 16.7% margins. The growth phase may be slowing, but strong cash generation and operational efficiency make it suitable for investors seeking reliability over excitement.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Sanofi ADR(SNY)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - GENERAL
USA
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.